FDA ISO 11608 Conformance for Prefilled Syringes in NDAs/BLAs

Does FDA require ISO 11608 testing for prefilled syringes in NDA/BLA approvals? What recent reviews actually say

Scope and short answer

This article looks at whether FDA has, in the last five years (2021 to mid-2026), explicitly required conformance to or testing against the ISO 11608 series (needle-based injection systems) for prefilled syringe (PFS) and PFS-with-needle-safety-device (PFS/NSD) constituent parts in NDA and BLA approvals. Autoinjector and prefilled-pen presentations are deliberately excluded.

Short answer: FDA review memoranda from CDER and CBER in this period routinely cite the ISO 11608 series for prefilled-syringe combination products, and in several cases treat conformance as the expected basis for device essential-performance verification. What you will not find is a statutory "requirement" in the strict sense. ISO 11608 is a voluntary FDA-recognized consensus standard, so sponsors submit a Declaration of Conformity and FDA reviewers assess whether the essential performance requirements (deliverable/dose volume, break-loose and glide force, needle-safety activation, and the associated preconditioning) have been verified against it. Where the data were judged inadequate, FDA has issued information requests and complete-response deficiencies demanding that verification. The distinction between "referenced," "expected," and "required" is the crux of the analysis below.

The regulatory status of ISO 11608 at FDA

ISO 11608 is not a mandatory rule; it is a consensus standard FDA has formally recognized, which lets a sponsor support a premarket submission with a Declaration of Conformity instead of full underlying data. The current editions were entered on FDA's recognized-standards list on 2022-05-30, each recognized in full ("Complete"):

The practical consequence for a PFS submission: FDA can expect the device constituent's essential performance (including the dose-volume and preconditioning provisions of Part 1 and the finished-container provisions of Part 3) to be demonstrated, but it does so by assessing conformance to a recognized standard, not by invoking a binding regulation. One CBER reviewer made the voluntary character explicit for a vaccine PFS, noting that the cited ISO standard "is not formally recognized by FDA. However, the standard can provide a framework," and that verification data were nonetheless necessary ¹³². (The exact standard number in that comment is redacted, so it may refer to a prefilled-syringe standard other than 11608.)

Prefilled-syringe products where FDA reviews cite ISO 11608 (2021 to 2026)

ANDEMBRY (garadacimab), BLA 761367

The clearest PFS/NSD example. The review lists the full applicable set for the device constituent: "ISO 11608-1:2022 ... Part 1: Needle-injection systems," "ISO 11608-3:2012 ... Part 3: Containers and integrated fluid paths," and "ISO 11608-5:2012 ... Part 5: Automated functions" ⁷⁴⁷⁵⁷⁶. The device is described as a "Pre-Filled Syringe (PFS) 200 mg assembled in a needle safety device (NSD)" (a separate autoinjector presentation also exists) ^204205206. FDA concluded that "Essential Performance Requirements are provided along with appropriate standards for this device types. (PFS with NSD and Autoinjector)," and that the design specifications, verification method, validation, biocompatibility and stability were acceptable ^747576206. This is the pattern of FDA treating ISO 11608 conformance as the appropriate performance basis for a PFS/NSD, though the memo does not phrase it as an FDA mandate for k-factor or preconditioning specifically ^747576206.

MNEXSPIKE (mRNA-1283 COVID-19 vaccine), STN 125835

The most direct conformance statement found. The CBER PFS device review memo for this "Prefilled Syringe Combination" states plainly: "Device is designed and tested to meet the applicable requirements of ISO 11608" ¹⁴⁵. The memo covers the "mRNA-1283 PFS" design verification and essential performance, and FDA asked for additional verification-testing and lot information ¹⁴⁵¹³³. The rows reviewed did not spell out preconditioning as a discrete FDA demand, but the conformance expectation is stated in FDA's own words ¹⁴⁵.

NYPOZI (filgrastim biosimilar), BLA 761126

A prefilled-syringe biosimilar. The review lists "ISO 11608-1 Needle-based injection system for medical use -- Requirements and test methods. Part 1" among the device standards for the PFS constituent ⁷⁸⁹⁰. On the pages reviewed, ISO 11608-1 appears as a referenced standard in the device evaluation rather than as an explicit FDA testing directive ⁷⁸⁹⁰.

FYLNETRA (pegfilgrastim biosimilar), BLA 761084

A single-use prefilled syringe assembled with a needle guard / needle safety device ^174175183. The device performance tables pair "11608-5" with dose accuracy and with ASTM D4169 shipping preconditioning ("ASTM 4169 | 11608-5," "ASTM 4169 | 11608-5 ... Dose Accuracy," "ASTM 4169 | 11608-5 CCI") ^166176177178. Beyond the standard citation, FDA actively required design-verification testing of the NSD, calling for "verification of performance of the NSD after necessary preconditioning (e.g. stability/aging to the end of shelf-life, simulated shipping/transportation per ASTM D4169)," and found a prior activation/override-force method inadequate ³⁶. So the preconditioning obligation is explicit, tied to the needle-safety essential performance, with ISO 11608-5 named in the specification table ^{36166176177178}.

PENMENVY (MenABCWY vaccine), BLA 125819

The MenB liquid component is delivered in a prefilled syringe ^134135136137. The design-input summary states "The prefilled syringe must meet functionality requirements from ISO (b)(4)," where the standard number is redacted ¹³¹. FDA required verification of device essential performance ("deliverable volume, break loose force, glide force, withdrawal force"), over shelf life and after shipping, and judged the submitted data inadequate because the testing was not reflective of proposed clinical use ^131132137. Because the standard number is redacted, this is best characterized as an explicit FDA testing requirement for PFS essential performance against an ISO prefilled-syringe standard that may be, but cannot be confirmed from the record to be, ISO 11608 ¹³¹¹³².

TICOVAC (tick-borne encephalitis vaccine), BLA 125740

A prefilled-syringe vaccine where FDA issued a complete-response device deficiency: "Based on the information provided in your submission, it does not appear as though your PFS has been tested to (b)(4) Requirements and test methods for finished prefilled syringes," warning that "[w]ithout this testing, it is not clear whether you have evaluated all of the design inputs," and requesting "evidence of verification per the relevant sections of (b)(4)" with a complete test report ¹⁵². The sponsor's response demonstrated "that PFS has been tested to (b)(4) Requirements and test methods for finished prefilled syringes," including finished container-closure critical dimensions ¹. This is a clear instance of FDA requiring finished-PFS test-method verification via a CR deficiency, but the redacted number ("Requirements and test methods for finished prefilled syringes") is at least as consistent with ISO 11040 as with ISO 11608-3, so it should not be counted as a confirmed ISO 11608 requirement ¹¹⁵².

Products cited by ISO 11608 but excluded (autoinjector / pen)

For completeness, the ISO 11608 references most explicitly framed around dose-accuracy k-factor and preconditioning in this period sit with excluded device types:

• BIMZELX (bimekizumab), BLA 761151 contains the textbook preconditioning language: "Dose Accuracy (extractable volume) ... Uses FDA recognized standard ISO 11608-1:2014, with all necessary conditions ... free fall, dry heat/cold storage, vibration," "Accuracy after preconditioning as designated in the standard," and "Injection time is measured at all preconditions in ISO 11608-1." The review states this applies to "a single dose and fixed dose autoinjector device," so it is an autoinjector, not a PFS, discussion ⁹⁹²⁰⁷.
• WEGOVY (semaglutide), NDA 215256: "Device performance was evaluated per ISO 11608-1 and ISO 11608-5," but the device is a single-dose pen-injector ⁸⁸.

These confirm that FDA's most explicit k-factor/preconditioning expectations under ISO 11608-1 are being applied, but the cleanest examples in the record attach to autoinjectors and pens rather than to bare prefilled syringes.

Bottom line for a regulatory submission

1. ISO 11608 is a fully recognized FDA consensus standard (Parts 1 to 7), so for a PFS or PFS/NSD constituent it functions as the expected performance framework via a Declaration of Conformity, not as a binding legal requirement ^{216217218219220221222}.
2. In the last five years FDA reviews have explicitly named ISO 11608 for prefilled-syringe products including ANDEMBRY (Parts 1/3/5) ⁷⁴⁷⁵⁷⁶, MNEXSPIKE ("designed and tested to meet the applicable requirements of ISO 11608") ¹⁴⁵, NYPOZI (Part 1) ⁷⁸⁹⁰, and FYLNETRA (Part 5, with ASTM D4169 preconditioning) ^166176177178.
3. Where FDA has come closest to "requiring" testing, it has done so through information requests and CR deficiencies on device essential performance and preconditioning: FYLNETRA (NSD performance after aging and simulated shipping) ³⁶, PENMENVY (deliverable volume, break-loose/glide/withdrawal force verification) ¹³¹¹³², and TICOVAC (finished-PFS test-method verification, standard number redacted) ¹¹⁵².
4. The specific "k-factor dose-volume" and Part 1 preconditioning provisions are demonstrably in FDA's toolkit, but the most explicit instances in the record attach to autoinjector/pen presentations (BIMZELX, WEGOVY) rather than to bare prefilled syringes ^8899207.

A reader planning a PFS or PFS/NSD combination-product submission should therefore expect FDA to look for a Declaration of Conformity to ISO 11608-1 and 11608-3 (and 11608-5 where a needle-safety automated function is present), backed by essential-performance verification (deliverable/dose volume, break-loose and glide force, needle-safety activation) demonstrated after the preconditioning designated in the standard and after simulated distribution and end-of-shelf-life aging. Whether a given review team frames that as "referenced," "expected," or a CR-level "requirement" has, in practice, depended on the adequacy of the sponsor's verification package.

Note on redactions: several vaccine PFS memos cite an ISO prefilled-syringe standard by title while the number is redacted as "(b)(4)." Those are flagged above and not counted as confirmed ISO 11608 requirements. A follow-up query on any single product can pull the full device-review section to resolve the exact part and edition.